EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY 4.0

A novel oncolytic herpes simplex virus type 2 induces polarization of tumor-associated macrophages and remodels the immune microenvironment in glioblastoma

Xin Yang, Shenglan Li, Yanjie Lan, Can Wang, Meng Zhang, Wenjing Zhao, Rong Zhang, Mengqian Huang, Zhuang Kang, Botao Zhang, Xiangyong Gu, Feng Chen und 3 weitere

Cancer Immunology, Immunotherapy · 30.05.2026 · 75 (8)

DOI: 10.1007/s00262-026-04440-w ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 30.05.2026. Verfasst von Xin Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioblastoma, Herpesvirus 2, Human, Oncolytic Virotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Talent Introduction Fund of Beijing Tiantan Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma multiforme (GBM) is a highly aggressive primary malignant brain tumor with limited survival despite multimodal therapy. Its profoundly immunosuppressive tumor microenvironment severely restricts treatment efficacy. Oncolytic viruses represent a promising therapeutic strategy, yet the immunological mechanisms underlying the antitumor activity of OH2 (oncolytic herpes simplex virus type 2) remain poorly defined.

Methods

The effects of OH2 were evaluated in GBM cell lines (U251, LN229 and GL261) by assessing cell viability, migration, apoptosis, and cell cycle distribution. Modulation of tumor-associated macrophages (TAMs) was examined in RAW264.7 and THP-1 cells through functional assays, RNA sequencing, Western blotting and pharmacologic inhibition. In vivo studies were performed in subcutaneous and orthotopic GBM models to assess tumor growth and immune alterations. Exploratory clinical observations were conducted in seven recurrent GBM patients (NCT05235074), including peripheral blood monocyte profiling, longitudinal immune monitoring and cytokine analysis.

Results

OH2 induced apoptotic and oncolytic cell death in GBM cells, while inhibiting cell proliferation and migration in vitro. In macrophage models, exposure to OH2-conditioned media enhanced proliferation and phagocytic activity and promoted M1-like polarization, accompanied by activation of JAK-STAT1 signaling. In vivo, OH2 suppressed tumor growth, promoted M1-like TAM polarization, reduced immunosuppressive macrophage populations, and increased recruitment of bone marrow-derived macrophages into the brain. Exploratory clinical observation suggested that changes in peripheral monocyte profiles may be associated with clinical benefit.

Conclusions

OH2 exerts antitumor activity in GBM through direct oncolysis and immune microenvironment modulation, highlighting its potential as an immunotherapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsGlioblastomaHerpesvirus 2, HumanOncolytic VirotherapyOncolytic VirusesTumor MicroenvironmentTumor-Associated MacrophagesAnimalsFemaleHumansMaleMiceApoptosisCell Line, TumorCell ProliferationXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Glioblastoma multiformeImmunotherapyJAK-STAT1 signalingOncolytic herpes simplex virus type 2 (OH2)Tumor immune microenvironment

Autor:innen und Institutionen

  • Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Department of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Hepato-Pancreato-Biliary Center, School of Clinical Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.
  • Wuhan Binhui Biopharmaceutical Co. Ltd., Wuhan, China.
  • Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, C…

Förderung

  • Talent Introduction Fund of Beijing Tiantan Hospital

Zitieren

APA

Yang, X., Li, S., Lan, Y., Wang, C., Zhang, M., Zhao, W., Zhang, R., Huang, M., Kang, Z., Zhang, B., Gu, X., Chen, F., Wu, Z., Liu, B., & Li, W. (2026). A novel oncolytic herpes simplex virus type 2 induces polarization of tumor-associated macrophages and remodels the immune microenvironment in glioblastoma. Cancer Immunology, Immunotherapy, 75(8). https://doi.org/10.1007/s00262-026-04440-w

Vancouver

Yang X, Li S, Lan Y, Wang C, Zhang M, Zhao W, et al. A novel oncolytic herpes simplex virus type 2 induces polarization of tumor-associated macrophages and remodels the immune microenvironment in glioblastoma. Cancer Immunology, Immunotherapy. 2026;75(8). doi:10.1007/s00262-026-04440-w

BibTeX
@article{Yang2026,
  author = {Yang, Xin and Li, Shenglan and Lan, Yanjie and Wang, Can and Zhang, Meng and Zhao, Wenjing and Zhang, Rong and Huang, Mengqian and Kang, Zhuang and Zhang, Botao and Gu, Xiangyong and Chen, Feng and Wu, Zhen and Liu, Binlei and Li, Wenbin},
  title = {A novel oncolytic herpes simplex virus type 2 induces polarization of tumor-associated macrophages and remodels the immune microenvironment in glioblastoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {8},
  doi = {10.1007/s00262-026-04440-w}
}
Kostenlos starten →